完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Cheng, Yi-An | en_US |
dc.contributor.author | Wu, Tung-Ho | en_US |
dc.contributor.author | Wang, Yun-Ming | en_US |
dc.contributor.author | Cheng, Tian-Lu | en_US |
dc.contributor.author | Chen, I-Ju | en_US |
dc.contributor.author | Lu, Yun-Chi | en_US |
dc.contributor.author | Chuang, Kuo-Hsiang | en_US |
dc.contributor.author | Wang, Chih-Kuang | en_US |
dc.contributor.author | Chen, Chiao-Yun | en_US |
dc.contributor.author | Lin, Rui-An | en_US |
dc.contributor.author | Chen, Huei-Jen | en_US |
dc.contributor.author | Liao, Tzu-Yi | en_US |
dc.contributor.author | Liu, En-Shuo | en_US |
dc.contributor.author | Chen, Fang-Ming | en_US |
dc.date.accessioned | 2020-10-05T02:01:56Z | - |
dc.date.available | 2020-10-05T02:01:56Z | - |
dc.date.issued | 2020-08-27 | en_US |
dc.identifier.uri | http://dx.doi.org/10.1186/s12951-020-00680-9 | en_US |
dc.identifier.uri | http://hdl.handle.net/11536/155354 | - |
dc.description.abstract | Background: Developing a universal strategy to improve the specificity and sensitivity of PEGylated nanoaparticles (PEG-NPs) for assisting in the diagnosis of tumors is important in multimodality imaging. Here, we developed the anti-methoxypolyethylene glycol (mPEG) bispecific antibody (BsAb; mPEG x HER2), which has dual specificity for mPEG and human epidermal growth factor receptor 2 (HER2), with a diverse array of PEG-NPs to confer nanoparticles with HER2 specificity and stronger intensity. Result: We used a one-step formulation to rapidly modify the nanoprobes with mPEG x HER2 and optimized the modified ratio of BsAbs on several PEG-NPs (Lipo-DiR, SPIO, Qdot and AuNP). The alpha HER2/PEG-NPs could specifically target MCF7/HER2 cells (HER2(++)) but not MCF7/neo1 cells (HER2(+/-)). The alpha HER2/Lipo-DiR and alpha HER2/SPIO could enhance the sensitivity of untargeted PEG-NPs on MCF7/HER2 (HER2(++)). In in vivo imaging, alpha HER2/Lipo-DiR and alpha HER2/SPIO increased the specific targeting and enhanced PEG-NPs accumulation at 175% and 187% on 24 h, respectively, in HER2-overexpressing tumors. Conclusion: mPEG x HER2, therefore, provided a simple one-step formulation to confer HER2-specific targeting and enhanced sensitivity and contrast intensity on HER2 positive tumors for multimodality imaging. | en_US |
dc.language.iso | en_US | en_US |
dc.subject | Bispecific antibody | en_US |
dc.subject | PEGylated nanoparticle | en_US |
dc.subject | Contrast agent | en_US |
dc.subject | Multimodality image | en_US |
dc.subject | Polyethylene glycol | en_US |
dc.subject | Anti-PEG antibody | en_US |
dc.subject | One-step formulation | en_US |
dc.subject | Tumor specificity | en_US |
dc.subject | Cancer image | en_US |
dc.title | Humanized bispecific antibody (mPEG x HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1186/s12951-020-00680-9 | en_US |
dc.identifier.journal | JOURNAL OF NANOBIOTECHNOLOGY | en_US |
dc.citation.volume | 18 | en_US |
dc.citation.issue | 1 | en_US |
dc.citation.spage | 0 | en_US |
dc.citation.epage | 0 | en_US |
dc.contributor.department | 生物科技學系 | zh_TW |
dc.contributor.department | Department of Biological Science and Technology | en_US |
dc.identifier.wosnumber | WOS:000566880500002 | en_US |
dc.citation.woscount | 0 | en_US |
顯示於類別: | 期刊論文 |